Midostaurin targets AML harbouring fms like tyrosine kinase 3 (FLT3) mutations, whereas enasidenib treats AML with an isocitrate dehydrogenase (IDH) 2 mutations. The gene discussed is IDH3A; the disease is acute myeloid leukemia.